The EBAG9 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of A-549 lung adenocarcinoma cells in which the EBAG9 gene has been disrupted, abolishing expression of the RCAS1 tumor-associated antigen. This polyclonal knockout cell pool provides a robust loss-of-function model for investigating RCAS1-dependent immune evasion and estrogen receptor-mediated signaling pathways without the artifacts associated with single-cell cloning.
The A-549 host cell line is an extensively validated epithelial model derived from a lung adenocarcinoma of a 58-year-old Caucasian male, harboring the oncogenic KRAS G12S driver mutation. As a widely used non-small cell lung cancer (NSCLC) model, A-549 cells recapitulate key features of tumor progression, including aberrant proliferation, migration, and interactions with the immune microenvironment, and are also employed in studies of pulmonary epithelial barrier function.
The EBAG9 gene encodes RCAS1 (receptor-binding cancer antigen expressed on SiSo cells), a type II transmembrane protein that serves as a tumor-associated antigen. RCAS1 is transcriptionally upregulated by estrogen?CER?? signaling, with additional regulatory input from NF-??B and AP-1 transcription factors. On the cell surface, RCAS1 engages a putative receptor on activated T lymphocytes and natural killer (NK) cells, triggering caspase-3-mediated apoptosis and thereby enabling tumor immune escape. Intracellularly, RCAS1 interacts with 14-3-3 scaffold proteins and can downregulate cyclin D1, implicating it in cell cycle modulation and cross-talk between endocrine and oncogenic pathways.
In the KRAS-mutant A-549 background, endogenous RCAS1 likely contributes to immune suppression and tumor aggressiveness. Disruption of EBAG9 in this polyclonal population permits detailed examination of how estrogen-driven RCAS1 expression intersects with KRAS signaling to influence apoptosis, proliferation, and the tumor microenvironment. This model is particularly suited for dissecting the interplay between hormone signaling and innate immune evasion in lung adenocarcinoma.
The EBAG9 Knockout A-549 Polyclonal Cells enable a diverse array of experimental approaches, including co-culture apoptosis assays with activated immune effector cells, flow cytometric analysis of apoptotic markers and immune checkpoint molecules, transwell migration and invasion assays, western blotting for RCAS1 and downstream targets, and RT-qPCR quantification of EBAG9 and estrogen-responsive genes. These applications support research into cancer immunotherapy development, estrogen signaling in NSCLC, and high-throughput screening of compounds that target the RCAS1-mediated immune escape axis. For further information, please contact Ascent Research.
